INOVIQ Ltd Responds to ASX Price Query
Key points
- No undisclosed information affecting IIQ's securities price
- Third-party research note influenced investor activity
- Clinical study results expected by June 2026
- Company complies with Listing Rules
Full summary
Inoviq Ltd (ASX: IIQ) responded to an ASX price query regarding the recent increase in its securities' price. The company confirmed no undisclosed information affecting the price. A third-party research note highlighting upcoming milestones for its EXO-OC test clinical study and in vitro CAR-exosome ovarian cancer data may have contributed to the heightened investor activity. The study, which commenced in April 2026, is on track for completion in June 2026. Inoviq Ltd assured compliance with the Listing Rules, particularly Rule 3.1.
Guidance
No specific financial guidance provided
Outlook
Clinical study results expected by June 2026
Summary generated by a large language model. Please interpret with care.